Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Malignant Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category
Malignant Neoplasm

Cancer Family

Malignant Neoplasm

CI-CAN-00000025CAExplore in graph →

20,116 active trials259 approved drugs3,741 evidence items

NCIt: C9305
OncoTree: MT
DOID: 162
UMLS CUI: C0006826

Overview
Statistics
Survival
Genomics442
Variants & evidence3741
Drugs424
Trials90685
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (4,349)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 4,001–4,025 of 4,349 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma.
· J Cell Mol Med · 2012 · PMID 22004109 · validated civic_curation pubmed
C609T polymorphism of NAD(P)H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicin.
· J Thorac Oncol · 2011 · PMID 21964527 · validated civic_curation pubmed
Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers.
· Clin Cancer Res · 2011 · PMID 21890455 · validated civic_curation pubmed
ATP-binding cassette B1 gene polymorphisms, mRNA expression and chemosensitivity to paclitaxel in non-small cell lung cancer cells.
· Respirology · 2011 · PMID 21883677 · validated civic_curation pubmed
Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment.
· Cancer Sci · 2010 · PMID 20088962 · validated civic_curation pubmed
Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells.
· Mol Cancer Ther · 2006 · PMID 17088436 · validated civic_curation pubmed
OCT4B1 promotes cell growth, migration and invasion suppressing sensitivity to οxaliplatin in colon cancer.
· Oncol Rep · 2015 · PMID 26398480 · validated

Showing 4,001–4,025 of 4,349 publications

← Previous
1
…
160
161
162
…
174
Next →

civic_curation

Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status.

· Target Oncol · 2016 · PMID 26668065 · validated civic_curation pubmed

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.

· Oncotarget · 2015 · PMID 26515464 · validated civic_curation pubmed

NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer.

· Oncotarget · 2016 · PMID 26716414 · validated civic_curation pubmed

Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.

· Oncotarget · 2016 · PMID 26678033 · validated civic_curation pubmed

Downregulation of cytokeratin 18 is associated with paclitaxel‑resistance and tumor aggressiveness in prostate cancer.

· Int J Oncol · 2016 · PMID 26892177 · validated civic_curation pubmed

Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma.

· Mol Cancer Res · 2014 · PMID 24962318 · validated civic_curation pubmed

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.

· J Clin Invest · 2006 · PMID 16906227 · validated civic_curation pubmed

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.

· Cancer Res · 2008 · PMID 18451166 · validated civic_curation pubmed

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

· Clin Cancer Res · 2008 · PMID 18594010 · validated civic_curation pubmed

Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.

· Clin Cancer Res · 2012 · PMID 22912387 · validated civic_curation pubmed

BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.

· Oncotarget · 2015 · PMID 26397223 · validated civic_curation pubmed

A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.

· Cancer Discov · 2014 · PMID 24631838 · validated civic_curation pubmed

Overexpression of pRB in human pancreatic carcinoma cells: function in chemotherapy-induced apoptosis.

· J Natl Cancer Inst · 2002 · PMID 11792751 · validated civic_curation pubmed

Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.

· Chem Biol Drug Des · 2011 · PMID 22034911 · validated civic_curation pubmed

Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.

· JAMA Otolaryngol Head Neck Surg · 2015 · PMID 25855885 · validated civic_curation pubmed

The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.

· Melanoma Res · 2003 · PMID 12777976 · validated civic_curation pubmed

SF3B1 mutations constitute a novel therapeutic target in breast cancer.

· J Pathol · 2015 · PMID 25424858 · validated civic_curation pubmed

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

· Cancer Res · 2008 · PMID 18829560 · validated civic_curation pubmed